Novo Nordisk A S annual shares outstanding
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Shares Outstanding History (NVO)
Novo Nordisk A S reported 4.44B shares outstanding at the end of fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 4.44B | 3.0M | +0.07% |
| 2024 | 2024-12-31 | 4.44B | −17.0M | −0.38% |
| 2023 | 2023-12-31 | 4.46B | −42.0M | −0.93% |
| 2022 | 2022-12-31 | 4.50B | −120.0M | −2.60% |
| 2021 | 2021-12-31 | 4.62B | 2.27B | +96.60% |
| 2020 | 2020-12-31 | 2.35B | −50.0M | −2.08% |
| 2019 | 2019-12-31 | 2.40B | — | — |
Novo Nordisk A S quarterly shares outstanding
Q4.19
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q4.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 4.44B | −176.0M | −3.81% |
| Q4 2024 | 2024-12-31 | 4.44B | 2.09B | +88.98% |
| Q4 2023 | 2023-12-31 | 4.46B | 2.06B | +85.75% |
| Q4 2022 | 2022-12-31 | 4.50B | — | — |
| Q4 2021 | 2021-12-31 | 4.62B | — | — |
| Q4 2020 | 2020-12-31 | 2.35B | — | — |
| Q4 2019 | 2019-12-31 | 2.40B | — | — |
Novo Nordisk A S shares outstanding trends
Over the last five reported fiscal years, Novo Nordisk A S's shares outstanding moved from 2.35B to 4.44B, a change of 2.09B. The latest reported quarter, Q4 2025, shows 4.44B.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S filings at SEC.gov ↗